Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Canadian Political Free-for-All -- Ignore unavailable to you. Want to Upgrade?

To: Alastair McIntosh who wrote (29642)	8/16/2023 5:40:03 PM
From: golfer72	1 Recommendation Recommended By longz Respond to of 37543

Oh give it a rest. There are dozens of studies proving IVM effectiveness. So tiresome

To: Alastair McIntosh who wrote (29642)	8/16/2023 9:51:31 PM
From: russet	1 Recommendation Recommended By longz Read Replies (1) \| Respond to of 37543

Yet many papers cite benefits of ivermectin for RNA and DNA viruses. There is a battle going on between scientists and governments that need to validate how they closed down their countries economies to stop covid. One of those battles is now for the democratic candidate for the U.S. president. We live in interesting times. Actually, all times seem interesting. Your twitter posts are not scientific papers, they are opinion pieces. The debate continues.

To: Alastair McIntosh who wrote (29642)	8/16/2023 10:01:35 PM
From: russet	2 Recommendations Recommended By longz teevee Read Replies (1) \| Respond to of 37543

Yet many papers cite benefits of ivermectin to inhibit replication of RNA and DNA viruses. There is a battle going on between scientists and governments that need to validate how they closed down their countries economies to stop covid. One of those battles is now for the democratic candidate for the U.S. president. We live in interesting times. Actually, all times seem interesting. Most of your twitter posts are not scientific papers, they are opinion pieces. The debate continues. The one that does claim to be a scientific paper gives the qualification below. They are paid by the governments that supported lockdowns. Do you understand scientific papers and what they are saying. It appears not. GTK receives revenue from YouTube for content on scientific misinformation and received conference travel support from the Institute for Clinical Research (Malaysia) for a talk given at the 15th National Conference for Clinical Research (NCCR). ACPA and RM declare no competing interests.} Now look at this company that actually has a scientifically proven theraputic for covid and variants of covid and other viruses. You are supporting the governments and pharma companies that are trying to suppress this theraputic. Idiot! You are on the dark side. Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients 2023-08-08 07:00 ET - News Release BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced the initiation of a clinical trial to treat Mild to Moderate COVID-19 patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial. Based on the success of Bioxytran’s Phase 2 trial in mild to moderate COVID-19 patients which achieved a 100% response rate by day 7 versus 6% in placebo the Central Drugs Standard Control Organization (CDSCO) in India approved the clinical trial protocol. The Company is initiating the first stage of its registrational trial which is a dose optimization study that will evaluate 3 different dosage levels against a matching placebo arm in a 5-day trial. The primary endpoints are time weighted average change in SARS-CoV-2 viral load and time to non-detection of viral shedding in outpatient swabs at various time intervals. Inclusion criteria allows for the recruitment of patients at high risk for progression to severe COVID-19 or patients with a Ct value less than 25. The next stage is large randomized double-blind placebo-controlled Phase 3 study with 408 patients looking to assess a statistically significant increase in responders rate at day 5 over placebo. “The initiation of this clinical trial is an important milestone for the pivotal COVID-19 program as well as the advancement in our pursuit of taming upper respiratory tract infections,” said Dr Leslie Ajayi, Bioxytran Chief Medical Officer. “This COVID-19 trial is simply a case study designed to showcase the platform potential of our drug. We are in the endemic phase of the pandemic and it’s just a matter of time before the next variant causes widespread illness. Right now there is a hot spot in the United Kingdom due to a rise in the EG.5.1 variant. The quick spreading nature of this variant is probably linked to the immune evasion from the SARS-CoV-2 vaccines and therapies that are waning in effect. This leaves a large unmet medical need for standard risk patients. We see the incredible potential of this glycovirology platform and recognize its ability to swiftly neutralize viruses thereby limiting contagion. If approved the chewable tablets would represent our first line of defense against the next pandemic and be deployed to these hot spots when they flare up.” About Bioxytran, Inc. Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com Bioxytran Peer-Reviewed Journal in ¢ € œVaccines ¢ € Contains Mechanism Capable of Targeting Future COVID-19 Mutations 2023-06-27 07:00 ET - News Release *Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)* *Complete elimination of* *most* *symptoms by day 7* *Galectin antagonist acts as an entry inhibitor for use in treatment* *of COVID-19* BOSTON, MASSACHUSETTS, June 27, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that the journal “Vaccines” released a peer-reviewed article, “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial”, which contains top-line safety and efficacy results of the Company’s randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value = 29) by day 7. Additionally, most of the symptoms completely disappeared in the group receiving the drug whereas the placebo group had 41.18% of patients that continued to experience chills, 29.41% that had a feverish sensation, and 35.29% that had a cough on day 7. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value =.001). Our analysis also revealed an 82% responders rate by day 3, which was statistically significant (p-value = .001). There were no drug-related serious adverse events (SAE’s) in the patient population or viral rebounds by day 14. The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial. The full text of the journal article is located at the following link. globenewswire.com “It’s clear in scientific circles that the risk of another pandemic in the next couple of years is very high,” said Dr Alben Sigamani, Bioxytran’s consulting Medical Director. “Driving future pandemics will be mutations of COVID-19 that have immune evasive properties negating the effect of widespread immunity and vaccines. We need a universal therapy that can treat any future mutations of COVID-19. Should the oral therapy of PL-M get regulatory approval, it lends itself well to being the new standard of care in treating upper respiratory infections like COVID-19. There is also very strong evidence that the dramatic reduction in viral load will stymie the transmissibility of future viruses. The journal suggests that the ability of PL-M to quickly reduce the viral load lends itself well to prophylaxis during pandemic conditions.” “When we look at how PL-M defeats COVID-19 it does it through a very efficient neutralization of the virus in regions of the body where the virus initially gains a foothold. The molecule interferes with the virus’s ability to enter tissue by blocking the “Galectin Fold.” The Galectin Fold is a universal region on the spike protein that his highly conserved and makes it an ideal binding region for our molecule. Based on this regions importance in facilitating viral entry it is unlikely to see any dominant mutations that would promote a loss of function in the virus. Endemic viruses tend to gain in function. We are committed to creating a platform technology that is able to battle any mutations.” About Bioxytran, Inc. Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com

To: Alastair McIntosh who wrote (29642)	8/17/2023 10:53:12 PM
From: russet	1 Recommendation Recommended By Alastair McIntosh Respond to of 37543

To: Alastair McIntosh who wrote (29642)	8/17/2023 10:55:57 PM
From: russet	Respond to of 37543

Remember that ivermectin use occurred throughout the world by many governments and doctors, successfully according to them. And there are a lot of lawsuits now about it in many countries that Pfizer can't control. Who knows what the outcome will be.